CANF
Income statement / Annual
Last year (2023), Can-Fite BioPharma Ltd.'s total revenue was $743,000.00,
a decrease of 8.27% from the previous year.
In 2023, Can-Fite BioPharma Ltd.'s net income was -$7.63 M.
See Can-Fite BioPharma Ltd.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$743,000.00
|
$810,000.00
|
$853,000.00
|
$763,000.00
|
$2.03 M
|
$3.82 M
|
$844,746.00
|
$169,500.00
|
$164,717.00
|
$0.00
|
| Cost of Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit |
$743,000.00 |
$810,000.00 |
$853,000.00 |
$763,000.00 |
$2.03 M |
$3.82 M |
$844,746.00 |
$169,500.00 |
$164,717.00 |
$0.00 |
| Gross Profit Ratio |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
0 |
| Research and Development
Expenses |
$5.98 M
|
$7.76 M
|
$9.85 M
|
$11.95 M
|
$10.98 M
|
$6.08 M
|
$5.27 M
|
$6.08 M
|
$3.86 M
|
$4.16 M
|
| General & Administrative
Expenses |
$2.96 M
|
$3.14 M
|
$3.85 M
|
$2.95 M
|
$3.06 M
|
$3.16 M
|
$2.92 M
|
$2.70 M
|
$2.70 M
|
$2.94 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$31,073.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$2.96 M
|
$3.14 M
|
$3.85 M
|
$2.95 M
|
$3.06 M
|
$3.16 M
|
$2.95 M
|
$2.70 M
|
$2.70 M
|
$2.94 M
|
| Other Expenses |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
-$20.64 M |
| Operating Expenses |
$8.94 M |
$10.91 M |
$13.70 M |
$14.90 M |
$14.04 M |
$9.23 M |
$8.22 M |
$8.80 M |
$6.58 M |
$7.13 M |
| Cost And Expenses |
$8.94 M |
$10.91 M |
$13.70 M |
$14.90 M |
$14.04 M |
$9.23 M |
$8.22 M |
$8.80 M |
$6.58 M |
$7.13 M |
| Interest Income |
$506,000.00 |
$222,000.00 |
$24,000.00 |
$44,000.00 |
$72,000.00 |
$51,000.00 |
$2.99 M |
$88,909.00 |
$1.92 M |
$11,556.00 |
| Interest Expense |
$14,000.00 |
$63,000.00 |
$22,000.00 |
$363,000.00 |
$427,000.00 |
$1.20 M |
$1.10 M |
$27,296.00 |
$564,342.00 |
$14,894.00 |
| Depreciation &
Amortization |
$15,000.00
|
$14,000.00
|
$13,999.00
|
$11,999.00
|
$13,999.00
|
$14,000.00
|
$18,999.00
|
$18,495.00
|
$16,394.00
|
$12,070.00
|
| EBITDA |
-$8.18 M
|
-$10.08 M
|
-$12.83 M
|
-$14.13 M
|
-$11.99 M
|
-$6.54 M
|
-$6.36 M
|
-$8.68 M
|
-$5.05 M
|
-$6.82 M
|
| EBITDA Ratio |
-11.01 |
-12.46 |
-15.06 |
-18.49 |
-5.88 |
-1.4 |
-5.19 |
-40.98 |
-27.19 |
0 |
| Operating Income Ratio
|
-11.03
|
-12.46
|
-15.06
|
-18.53
|
-5.91
|
-1.42
|
-8.73
|
-50.94
|
-38.95
|
0
|
| Total Other
Income/Expenses Net |
$561,000.00
|
-$77,000.00
|
$227,000.00
|
-$304,000.00
|
-$618,000.00
|
-$1.15 M
|
$781,000.00
|
$319,000.00
|
$1.39 M
|
$840,282.00
|
| Income Before Tax |
-$7.63 M |
-$10.17 M |
-$12.62 M |
-$14.44 M |
-$12.63 M |
-$6.57 M |
-$4.95 M |
-$6.99 M |
-$5.06 M |
-$6.29 M |
| Income Before Tax Ratio
|
-10.27
|
-12.56
|
-14.79
|
-18.93
|
-6.21
|
-1.72
|
-5.86
|
-41.25
|
-30.72
|
0
|
| Income Tax Expense |
$0.00 |
$63,000.00 |
-$20,000.00 |
$363,000.00 |
$427,000.00 |
$4,000.00 |
$29,922.00 |
$29,116.00 |
$4,354.89 |
$5,906.63 |
| Net Income |
-$7.63 M |
-$10.17 M |
-$12.62 M |
-$14.44 M |
-$12.63 M |
-$6.57 M |
-$6.34 M |
-$8.26 M |
-$6.24 M |
-$6.10 M |
| Net Income Ratio |
-10.27 |
-12.64 |
-14.77 |
-19.4 |
-6.42 |
-1.72 |
-5.88 |
-40.69 |
-29.12 |
0 |
| EPS |
-0.006 |
-0.0125 |
-0.0275 |
-0.0423 |
-0.15 |
-0.17 |
-0.19 |
-0.3 |
-0.27 |
-0.35 |
| EPS Diluted |
-0.006 |
-0.0125 |
-0.0228 |
-0.0403 |
-0.15 |
-0.17 |
-0.19 |
-0.3 |
-0.27 |
-0.35 |
| Weighted Average Shares
Out |
$1.28 B
|
$815.80 M
|
$458.88 M
|
$341.51 M
|
$85.91 M
|
$38.90 M
|
$32.53 M
|
$27.69 M
|
$22.95 M
|
$17.55 M
|
| Weighted Average Shares
Out Diluted |
$1.28 B
|
$815.75 M
|
$553.08 M
|
$358.41 M
|
$85.91 M
|
$38.90 M
|
$32.53 M
|
$27.69 M
|
$22.95 M
|
$17.55 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
